📊 Analyst Consensus & Targets
- Analyst Rating: Buy
- Price Target: $100.09524
- Sector: Healthcare – Biotechnology
💡 The Growth Thesis
Buy Consensus: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. Analysts project a 1.3% potential upside. Currently trading at a Forward P/E of 12.901869.